SEC Company Response from Aditxt, Inc. (ADTX) (CIK 0001726711) (ADTX) — Aug 6, 2018
Aditxt, Inc. (ADTX) (CIK 0001726711)
Date: Aug. 6, 2018 · CIK: 0001726711 · Accession: 0001615774-18-007627
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-10825
Letter
Re:
August 6, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
ADiTx Therapeutics, Inc.
Amendment No. 3 to Offering Statement on Form 1-A
Filed on July 18, 2018
File No. 024-10825
Ladies and Gentlemen:
This letter sets forth the responses of ADiTx Therapeutics, Inc., a Delaware corporation (the “Company” or “we”), to the oral comments received from the Staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) concerning Amendment No. 3 to the Company’s Offering Statement on Form 1-A (File No. 024-10825) filed with the Commission on July 18, 2018 (the “Amended Offering Statement”).
References in the text of the responses herein to captions and page numbers are to Amendment No. 4 to the Company’s Form 1-A (the “Fourth Amended Offering Statement”), which is being filed herewith.
In addition to addressing the Staff’s oral comments, we note that we have elected to increase the Minimum Offering Amount to $7,320,000. We have updated disclosure through the Fourth Amended Offering Statement to reflect this change.
Amendment No. 3 to Offering Statement on Form 1-A
QUESTION: Please fill in all remaining blanks in the Offering Circular and/or advise whether the Company intends to rely on Rule 253. Please also confirm that all other outstanding Staff comments have been resolved.
RESPONSE: As requested, we have filled in all remaining blanks in the Fourth Amended Offering Statement. We respectfully submit and confirm that these changes address all outstanding comments from the Staff.
Very truly yours,
/s/ AMRO ALBANNA
Show Raw Text
CORRESP
1
filename1.htm
August 6, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re:
ADiTx Therapeutics, Inc.
Amendment No. 3 to Offering Statement on Form 1-A
Filed on July 18, 2018
File No. 024-10825
Ladies and Gentlemen:
This letter sets forth
the responses of ADiTx Therapeutics, Inc., a Delaware corporation (the “Company” or “we”),
to the oral comments received from the Staff (the “Staff”) of the U.S. Securities and Exchange Commission (the
“Commission”) concerning Amendment No. 3 to the Company’s Offering Statement on Form 1-A (File No. 024-10825)
filed with the Commission on July 18, 2018 (the “Amended Offering Statement”).
References in the text
of the responses herein to captions and page numbers are to Amendment No. 4 to the Company’s Form 1-A (the “Fourth
Amended Offering Statement”), which is being filed herewith.
In addition to addressing
the Staff’s oral comments, we note that we have elected to increase the Minimum Offering Amount to $7,320,000. We have updated
disclosure through the Fourth Amended Offering Statement to reflect this change.
Amendment No. 3 to Offering Statement on Form 1-A
QUESTION:
Please fill in all remaining blanks in the Offering Circular and/or advise whether the Company intends to rely on Rule 253. Please
also confirm that all other outstanding Staff comments have been resolved.
RESPONSE: As requested,
we have filled in all remaining blanks in the Fourth Amended Offering Statement. We respectfully submit and confirm that these
changes address all outstanding comments from the Staff.
Very truly yours,
/s/ AMRO ALBANNA
Amro Albanna
Chief Executive Officer
Cc: Richard A. Friedman
Sheppard,
Mullin, Richter & Hampton LLP
ADiTx
Therapeutics, Inc.
11161
Anderson St., Suite 105-10014 Loma Linda, CA 92354
www.aditxt.com